Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) EBT: 2023-2025

Historic EBT for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' EBT rose 19.62% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 109.44%. This contributed to the annual value of $1.7 billion for FY2024, which is 803.97% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported EBT of -$35.3 million as of Q3 2025, which was down 23.05% from -$28.7 million recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' EBT peaked at $1.9 billion during Q2 2024, and registered a low of -$92.0 million during Q4 2023.
  • Moreover, its 3-year median value for EBT was -$45.9 million (2024), whereas its average is $138.8 million.
  • Per our database at Business Quant, Inhibrx Biosciences' EBT skyrocketed by 3,898.37% in 2024 and then crashed by 101.54% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' EBT (Quarterly) stood at -$92.0 million in 2023, then surged by 47.96% to -$47.9 million in 2024, then climbed by 19.62% to -$35.3 million in 2025.
  • Its EBT stands at -$35.3 million for Q3 2025, versus -$28.7 million for Q2 2025 and -$43.3 million for Q1 2025.